SCHEMBL2800587

SCHEMBL2800587

Cc1ccc(C2CCN(C(=O)c3cnc4c(Br)cnn4c3NCc3ccccc3)CC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT6 P42226 1/20 0.42
ENPP2 Q13822 1/20 0.42
TUBB4A P04350 1/20 0.41
TUBB P07437 1/20 0.41
TUBA3C P0DPH7 1/20 0.41
TUBA1B P68363 1/20 0.41
TUBA4A P68366 1/20 0.41
TUBB4B P68371 1/20 0.41
TUBB3 Q13509 1/20 0.41
TUBB2A Q13885 1/20 0.41
TUBB8 Q3ZCM7 1/20 0.41
TUBA3E Q6PEY2 1/20 0.41
TUBA1A Q71U36 1/20 0.41
TUBA1C Q9BQE3 1/20 0.41
TUBB6 Q9BUF5 1/20 0.41
TUBB2B Q9BVA1 1/20 0.41
TUBB1 Q9H4B7 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
AXL P30530 1/20 0.40
FLT3 P36888 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2802845 0.94 STAT6 (0.41) STAT6ENPP2AXLFLT3TYRO3
SCHEMBL2801418 0.92 CHRM4 (0.42) STAT6ENPP2TUBB4ATUBBTUBA3C
SCHEMBL2798414 0.91 STAT6 (0.43) STAT6ENPP2TUBB4ATUBBTUBA3C
SCHEMBL2801457 0.91 AXL (0.40) STAT6ENPP2SMN1; SMN2AXLFLT3
SCHEMBL2800526 0.88 AXL (0.43) STAT6TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2800833 0.87 GSK3B (0.47) MGLL
SCHEMBL2802391 0.86 SMN1; SMN2 (0.41) STAT6ENPP2TUBB4ATUBBTUBA3C
SCHEMBL2801855 0.86 PDE4B (0.46) SMN1; SMN2TP53MAPTTDP1NPC1
SCHEMBL2800915 0.86 ALDH1A1 (0.43) NPC1MEN1KMT2AKDM4EALDH1A1
SCHEMBL2802442 0.86 AVPR1A (0.41) SMN1; SMN2THRBTP53MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 STAT6 146/4885ENPP2 1017/4885TUBB4A 761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.